NASDAQ:ZGNX - Zogenix Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$61.35 +5.45 (+9.75 %)
(As of 07/16/2018 06:30 AM ET)
Previous Close$55.90
Today's Range$56.00 - $62.75
52-Week Range$10.05 - $58.30
Volume3.15 million shs
Average Volume865,031 shs
Market Capitalization$2.16 billion
P/E Ratio-15.26
Dividend YieldN/A
Zogenix logoZogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.

Receive ZGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for ZGNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio12.19
Quick Ratio12.19


Trailing P/E Ratio-15.26
Forward P/E Ratio-15.77
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.82 million
Price / Sales220.04
Cash FlowN/A
Price / CashN/A
Book Value$8.80 per share
Price / Book6.97


EPS (Most Recent Fiscal Year)($4.02)
Net Income$-126,810,000.00
Net MarginsN/A
Return on Equity-66.94%
Return on Assets-40.43%


Outstanding Shares35,220,000
Market Cap$2,160.93

The Truth About Cryptocurrencies

Zogenix (NASDAQ:ZGNX) Frequently Asked Questions

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) announced its earnings results on Wednesday, May, 9th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.74) by $0.13. During the same period in the previous year, the business posted ($0.86) EPS. View Zogenix's Earnings History.

What price target have analysts set for ZGNX?

5 analysts have issued 12 month price targets for Zogenix's stock. Their forecasts range from $54.00 to $69.00. On average, they expect Zogenix's share price to reach $61.00 in the next year. This suggests that the stock has a possible downside of 0.6%. View Analyst Ratings for Zogenix.

What is the consensus analysts' recommendation for Zogenix?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Zogenix stock?

Here are some recent quotes from research analysts about Zogenix stock:
  • 1. According to Zacks Investment Research, "Zogenix, Inc. is a pharmaceutical company engaged in the development and commercialization of treatment products for central nervous system disorders and pain. Its first commercial product, Sumavel™ DosePro™ is a needle-free Delivery System used in the treatment of acute migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, ZX002, is a novel, oral and single-entity controlled-release formulation of hydrocodone used for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix, Inc. is headquartered in San Diego, CA. " (6/21/2018)
  • 2. Mizuho analysts commented, "We are confident ahead of this data and we expect the readout to be an important share moving event and the last major hurdle prior to submission of the NDA." (5/10/2018)

Who are some of Zogenix's key competitors?

Who are Zogenix's key executives?

Zogenix's management team includes the folowing people:
  • Dr. Stephen J. Farr, Co-Founder, CEO, Pres & Director (Age 59)
  • Mr. Roger L. Hawley B.S., Co-Founder & Director (Age 65)
  • Mr. Michael P. Smith, Exec. VP, CFO, Treasurer & Sec. (Age 50)
  • Dr. Bradley S. Galer, Exec. VP & Chief Medical Officer (Age 56)
  • Dr. Gail M. Farfel, Exec. VP & Chief Devel. Officer (Age 54)

Has Zogenix been receiving favorable news coverage?

Media stories about ZGNX stock have trended somewhat positive on Monday, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zogenix earned a media sentiment score of 0.11 on Accern's scale. They also assigned news headlines about the company an impact score of 45.17 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Zogenix's major shareholders?

Zogenix's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Xact Kapitalforvaltning AB (0.02%). Company insiders that own Zogenix stock include Bradley S Galer, Cam L Garner, Gail M Farfel, Life Sciences Maste Perceptive, Renee P Tannenbaum and Roger Hawley. View Institutional Ownership Trends for Zogenix.

Which major investors are buying Zogenix stock?

ZGNX stock was bought by a variety of institutional investors in the last quarter, including Xact Kapitalforvaltning AB. Company insiders that have bought Zogenix stock in the last two years include Bradley S Galer, Life Sciences Maste Perceptive and Renee P Tannenbaum. View Insider Buying and Selling for Zogenix.

How do I buy shares of Zogenix?

Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zogenix's stock price today?

One share of ZGNX stock can currently be purchased for approximately $61.35.

How big of a company is Zogenix?

Zogenix has a market capitalization of $2.16 billion and generates $9.82 million in revenue each year. The company earns $-126,810,000.00 in net income (profit) each year or ($4.02) on an earnings per share basis. Zogenix employs 68 workers across the globe.

How can I contact Zogenix?

Zogenix's mailing address is 5858 Horton Street Suite 455, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected]

MarketBeat Community Rating for Zogenix (NASDAQ ZGNX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  290 (Vote Outperform)
Underperform Votes:  186 (Vote Underperform)
Total Votes:  476
MarketBeat's community ratings are surveys of what our community members think about Zogenix and other stocks. Vote "Outperform" if you believe ZGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.